Questions are answered by experts at the Oregon Health Authority, other state agencies or community partners. Questions and ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

You’re reading The Checkup With Dr. Wen, a newsletter on how to navigate medical and public health challenges. Click here to ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

Kennedy wants to expand the injury compensation program to include COVID-19 vaccines, while also stretching the “statute of ...

"An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for Covid-19 combination ...